NOVARTIS logo.jpg
Novartis renews commitment to neglected tropical disease and malaria elimination, investing USD 250 million over five years to research and develop new treatments
June 22, 2022 20:01 ET | Novartis Pharma AG
Novartis endorses the Kigali Declaration on neglected tropical diseases, pledging USD 250 million to advance R&D of new treatments against NTDs and malaria over five yearsCommitment includes USD...
Featured Image for Experimental Biology and Medicine
New Study Identifies Potential Immunotherapy Target for Malaria
May 09, 2022 10:00 ET | Experimental Biology and Medicine
WASHINGTON, May 09, 2022 (GLOBE NEWSWIRE) -- A recently published article in Experimental Biology and Medicine (Volume 247, Issue 8, April, 2022) identifies a new target for malaria treatment. The...
Insights on the Malaria Diagnostics Global Market to 2026 - by Technology, End-use and Region
March 25, 2022 08:58 ET | Research and Markets
Dublin, March 25, 2022 (GLOBE NEWSWIRE) -- The "Malaria Diagnostics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to...
Global Hepatitis Diagnostic Tests Market
Insights on the Hepatitis Diagnostic Tests Global Market to 2027 - Focus on Blood Tests, Imaging Tests and Liver Biopsies
March 02, 2022 07:23 ET | Research and Markets
Dublin, March 02, 2022 (GLOBE NEWSWIRE) -- The "Hepatitis Diagnostic Tests Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to...
Vantage Market Research.png
Global Hydroxychloroquine Market Projected to Reach Over USD 2,598.6 Million by 2028 - Vantage Market Research
February 16, 2022 07:39 ET | Vantage Market Research
WASHINGTON, Feb. 16, 2022 (GLOBE NEWSWIRE) -- The Global Hydroxychloroquine Market size is expected to reach over USD 2,598.6 Million by 2028, exhibiting a Compound Annual Growth Rate (CAGR) of 5.7%...
Vir Biotechnology Launches New Antibody Research Initiative Aimed at a Functional Cure for HIV and Prevention of Malaria
January 13, 2022 09:05 ET | Vir Biotechnology, Inc.
– New commitment from the Bill & Melinda Gates Foundation supports the development of Vir’s novel “vaccinal antibody” technology as another important step in the fight to address global...
Global Dengue Testing Markets, 2026 - ELISA-based Tests Expected to Dominate, Asia-Pacific the Fastest Growing Market
December 22, 2021 08:13 ET | Research and Markets
Dublin, Dec. 22, 2021 (GLOBE NEWSWIRE) -- The "Dengue Testing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021-2026)" report has been added to's offering. The...
Kainomyx logo.jpg
Kainomyx Announces New Funding to Advance Programs Focused on Malaria and Other Parasitic Diseases
October 26, 2021 15:41 ET | Kainomyx Inc.
PALO ALTO, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Kainomyx, Inc., founded in September 2019 and financed with $7.5M in May 2020, announced a new round of funding of $7.97M to advance its programs...
Gemeinsames Kommuniq
Gemeinsames Kommuniqué: BioNTech evaluiert Optionen zur Herstellung von mRNA-Impfstoffen in Ruanda und Senegal zur Unterstützung einer langfristigen Impfstoffversorgung in Afrika
August 27, 2021 07:15 ET | BioNTech SE
BERLIN, DEUTSCHLAND, 27. August, 2021 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, „BioNTech” oder „das Unternehmen”) gab heute bekannt, den Aufbau nachhaltiger Produktionsmöglichkeiten für...
Joint Communiqué: Bi
Joint Communiqué: BioNTech Evaluates mRNA Vaccine Manufacturing Solutions in Rwanda and Senegal to Improve Long-Term Vaccine Supply
August 27, 2021 07:15 ET | BioNTech SE
BERLIN, GERMANY, August 27, 2021 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) agreed today to evaluate the establishment of sustainable vaccine manufacturing capabilities...